First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors

A. Yap, Timothy; S.P. Tan, David; Terbuch, Angelika; Caldwell, Reece; Guo, Christina; Cher Goh, Boon; Heong, Valerie; R. Md. Haris, Noor; Bashir, Saira; Drew, Yvette; S. Hong, David; Meric‐Bernstam, Funda; Wilkinson, Gary; Hreiki, Joseph; M. Wengner, Antje; Bladt, Friedhelm; Schlicker, Andreas; Ludwig, Matthias; Zhou, Yinghui; Liu, Li; Bordia, Sonal; Plummer, Ruth; Lagkadinou, Eleni; S. de Bono, Johann

doi:10.1158/2159-8290.cd-20-0868

Public

First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors

Published in Cancer Discovery • Sep 29, 2020

Authors:

Timothy A. Yap

David S.P. Tan

Angelika Terbuch

Abstract

Abstract Targeting the ataxia telangiectasia and RAD3-related (ATR) enzyme represents a promising anticancer strategy for tumors with DNA damage response (DDR) defects and replication stress, including inactivation of ataxia telangiectasia mutated (ATM) signaling. We report the dose-escalation porti...

Subject

Ataxia-telangiectasia

Medicine

Adverse effect

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!